Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 247,054 shares, a growth of 136.9% from the February 12th total of 104,299 shares. Based on an average daily volume of 4,663,750 shares, the days-to-cover ratio is presently 0.1 days. Approximately 3.3% of the shares of the company are short sold. Approximately 3.3% of the shares of the company are short sold. Based on an average daily volume of 4,663,750 shares, the days-to-cover ratio is presently 0.1 days.

Ernexa Therapeutics Stock Up 4.9%

Shares of Ernexa Therapeutics stock traded up $0.02 on Friday, reaching $0.32. 3,433,063 shares of the stock were exchanged, compared to its average volume of 1,852,387. The business has a 50 day moving average price of $0.75 and a two-hundred day moving average price of $1.13. The firm has a market capitalization of $2.55 million, a price-to-earnings ratio of -0.11 and a beta of 6.58. Ernexa Therapeutics has a twelve month low of $0.27 and a twelve month high of $4.20.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 70.55% of the company’s stock.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.